Authored by Cello Health BioConsulting, now part of Lumanity

I’m no fortune-teller.  But I can predict with a reasonable amount of certainty that, in the next week or so, we’ll see a press release that more or less says the following: “Mega venture round for CAR-T therapy platform company coming out of stealth-mode with an A-list cadre of scientific co-founders, a C-suite that knows how to raise funds and get the job done, and a value proposition pointed at the target painted on the backs of early-mover products.”  While money is clearly not falling from the sky, there are massive opportunities for cell therapy newcos with their ducks in a row.

Read the full article

To read the full article, please complete the form below.

Sign me up to receive regular insights from Lumanity
This field is for validation purposes and should be left unchanged.